Relmada Therapeutics Inc.
RLMD | NASDAQ
$4.16
+$0.04 (+0.97%)
At close: Sep 21, 2026, 4:00 PM ET
$4.16
$0 (0.00%)
After-hours:
Sep 21, 2026, 7:30 PM ET
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Income | -59.1M | -83.89M | -103.7M | -161.25M | -125.7M | -60.84M |
Interest Income | 1.4M | 3.53M | 5.15M | 2.66M | 1.2M | 1.4M |
Pretax Income | -57.39M | -79.98M | -98.79M | -157.04M | -125.75M | -59.46M |
Net Income | -57.39M | -79.98M | -98.79M | -157.04M | -125.75M | -59.46M |
Selling & General & Admin | 311.9K | 37.72M | 48.9M | 47.93M | 35.08M | 24.87M |
Research & Development | 744.56K | 46.18M | 54.81M | 113.32M | 90.62M | 35.97M |
Other Expenses | 58.04M | n/a | n/a | 923 | n/a | n/a |
Operating Expenses | 59.1M | 83.89M | 103.7M | 161.25M | 125.7M | 60.84M |
Interest Expense | n/a | n/a | n/a | n/a | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 59.1M | 83.89M | 103.7M | 161.25M | 125.7M | 60.84M |
Income Tax Expense | n/a | n/a | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 39.48M | 30.16M | 30.1M | 29.63M | 17.55M | 15.59M |
Shares Outstanding (Diluted) | 39.48M | 30.16M | 30.1M | 29.63M | 17.55M | 15.59M |
EPS (Basic) | -1.45 | -2.65 | -3.28 | -5.30 | -7.16 | -3.81 |
EPS (Diluted) | -1.45 | -2.65 | -3.28 | -5.30 | -7.16 | -3.81 |
EBITDA | -57.39M | -79.98M | 4.91M | -157.04M | -125.75M | -59.33M |
EBIT | -57.39M | -79.98M | -98.79M | -157.04M | -125.75M | -59.34M |
Depreciation & Amortization | n/a | n/a | 103.7M | 2K | 1.26K | 3.75K |
Add to Watchlist
Select watchlists to add or remove RLMD